title: [Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib].
abstract: A seventy-six year old female patient with chronic myelogenous leukemia (CML), (chronic phase), was treated with imatinib and obtained a major cytogenetic response after 6 months of treatment. However, resistance to imatinib appeared 9 months later due to an ABL gene point mutation, and the patient's platelet count and BCR/ABL positive rate had remarkably increased. We discontinued imatinib and used IFNalpha or hydroxyurea, resulting in the disappearance of the ABL gene mutation clone. After that, we obtained a secondary hematologic response with the administration of imatinib.
authors.affiliation: Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Murase
authors.forename: Takuya
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Naoko
authors.initials: N
authors.lastname: Takeuchi
authors.forename: Akihito
authors.initials: A
authors.lastname: Fujimi
authors.forename: Rishu
authors.initials: R
authors.lastname: Takimoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Terui
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hirayama
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Niitsu
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002999:Clone Cells; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D016313:Genes, abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate